The stock has more than doubled since July and has tripled since February, but the gains are not done, according to TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio.
Agios Pharmaceuticals AGIO data by YCharts
On CNBC's "Cramer's Stop Trading" Segment, he complimented CEO David Schenkein, saying he's done a "remarkable job." Cramer reminded viewers that Celgene (CELG) , one of his favorite biotechs, holds a large stake in the company.
Agios' leukemia drug has a very impressive response rate, Cramer said, concluding that "Agios is going much higher."
-- Written by Bret Kenwell